In Vitro Cardiotoxicity
Creative Bioarray provides both standard and novel in vitro drug cardiotoxicity services using iPS cell derived or ES cell derived cardiomyocytes from different species to test and identify cardiotoxic compounds. We offer cardiotoxicity assays such as classical hERG safety assay, QT prolongation assay, arrhythmogenic liability screening, Comprehensive in Vitro Proarrhytmia Assay (CiPA), and customized assays.
With cardiotoxicity being one of the leading causes of safety-related compound attrition and drug withdrawals, cardiac liability remains one of the major hurdles in the drug discovery process. Cardiac arrhythmias, as the most common manifestations of drug-induced cardiotoxicity, are often life-threatening and may result in severe cardiac complications or even sudden death. Therefore, extensive efforts have been put into the development of predictive and reliable assays and technologies to effectively detect possible acute and subtle cardiotoxic effects of test compounds and to minimize both risk and overall cost earlier in the drug development pipeline.
These technologies include:
- Microelectrode array (MEA), a high-throughput, functional platform that can be applied to the detection of prolongation, alterations in beat rate, proarrhythmic events, and dysregulation of conduction by measuring the extracellular voltage of beating cardiomyocyte cultures;
- High content screening (HCS) that allows simultaneous detection and monitoring of multiple parameters and phenotypes via fluorescent imaging.
Creative Bioarray offers the following in vitro cardiotoxicity assays using MEA and HCS techniques:
hERG safety assay
QT prolongation assay
Arrhythmogenic liability screening
Comprehensive in vitro proarrhytmia assay (CiPA)
Calcium transient assay
Changes in calcium signal can be detected by treating iPSC-derived cardiomyocytes with a fluorescent calcium-sensitive dye.
Calcium transient service allows evaluation of the acute and long-term effects of drugs on electrophysiology of cardiomyocytes.
Cardiac marker detection
Creative Bioarray offers both classic and novel cell culture models for evaluation of cardiotoxicity:
- Classic 2D models
- 3D cardiotoxicity assay
iPSC- / ES-derived cardiomyocytes
With 3D cardiomyocyte spheroids and high-content imaging devices, Creative Bioarray is able to provide a cardiotoxicity service that monitors the effects of compounds on cardiomyocytes at a structural and phenotypic level.
Having gained years of experience, Creative Bioarray is capable of providing considerate and reliable services of high quality for our clients. Our highly experienced experts are ready to support you with their knowledge. If you have any questions or special needs, please contact us for support. We look forward to working with you in the near future.
- Shinde, Vaibhav, Umesh Chaudhari, Isaia Sotiriadou, Jürgen Hescheler, and Agapios Sachinidis. "In Vitro Methods for Cardiotoxicity Testing." In Vitro Toxicology Systems (2014): 45-77.
- Cavero, Icilio, and Henry Holzgrefe. "Comprehensive in vitro Proarrhythmia Assay, a novel in vitro/in silico paradigm to detect ventricular proarrhythmic liability: a visionary 21st century initiative." Expert opinion on drug safety13.6 (2014): 745-758.
For research use only. Not for any other purpose.